The abstract is read at the publisher; the summary is JClub's.
CF newborn screening evolved from measuring immunoreactive trypsinogen (IRT) on dried blood spots to mandatory CFTR gene sequencing, with adoption of next generation sequencing (NGS) accelerating after a 2025 recommendation.
- Why it matters: Programs needed a way to diagnose infants equitably across race/ethnicity and to expand beyond limited variant detection as recommended CFTR variant panels grew.
- What they did: NBS uses a two-tier workflow: IRT measurement followed by CFTR variant testing, progressing from a single GRCh38 deletion to panels of 39–70 variants and then to CFTR sequencing, with NGS replacing Sanger for efficiency and cost.
- The result: In 2025, the United States Cystic Fibrosis Foundation recommended CFTR sequencing for CF NBS, and this is linked to rapid growth of NGS adoption in states’ CF NBS programs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.